A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer

Senan, S.; Cardenal, F.; Vansteenkiste, J.; Stigt, J.; Akyol, F.; De Neve, W.; Bakker, J.; Dupont, J.; Scagliotti, G.; Ricardi, U.; van Meerbeeck, J.

doi:10.1093/annonc/mdq388

A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer

Senan S., Cardenal F., Vansteenkiste J., Stigt J., Akyol F., De Neve W., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.22, sa.3, ss.553-558, 2011 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 3
Basım Tarihi: 2011
Doi Numarası: 10.1093/annonc/mdq388
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.553-558
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: In stage III non-small-cell lung cancer (NSCLC), the role of systemic chemotherapy preceding or following concurrent chemo-radiotherapy (CT-RT) is unclear. We carried out a randomized phase II study to study the toxicity involved-field CT-RT with either induction or consolidation cisplatin-docetaxel (Taxotere).